This information is intended for use by US healthcare providers only. Visit the RELIEF Clinical Trial >>

Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment

Contact RESPONSE

For more information

To enroll a patient in RESPONSE or to find out more, please contact the Incyte Clinical Trials Hotline at
1-877-4-PV-TRIAL (1-877-478-8742).

This Web site is for US healthcare professionals only for the RESPONSE trial. Ruxolitinib is an investigational compound for the treatment of patients with polycythemia vera (PV). Its efficacy and safety have not been established in this patient population. There is no guarantee that this compound will become commercially available for use in PV patients.

Last updated May 2012.